According to Fortune, GlycoMimetics has postponed its IPO that was to have launched on Friday. No reason has been given nor is there a date scheduled for the IPO to debut. The publication reported that the company plans on selling 4 million shares at between $14 and $16 per share. It will trade on the NASDAQ under the ticker symbol “GLYC.” Jefferies and Barclays are acting as lead underwriters. Based in Gaithersburg, MD, GlycoMimetics is a biotech company focused on developing glycomimetic drugs. It is backed by New Enterprise Associates, Genzyme Ventures, The Novartis Venture Fund, Anthem Capital and Alliance Technology Ventures.